Bristol-Myers Squibb (NYSE:BMY – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $0.75-0.95 for the period, compared to the consensus EPS estimate of $0.70. The company issued revenue guidance of +5% yr/yr to $47.26 billion, compared to the consensus revenue estimate of $46.78 billion. Bristol-Myers Squibb also updated its FY 2024 guidance to 0.750-0.950 EPS.
Bristol-Myers Squibb Price Performance
Shares of Bristol-Myers Squibb stock opened at $54.70 on Thursday. The firm has a market capitalization of $110.88 billion, a PE ratio of -16.99, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $55.03. The business’s 50-day moving average price is $50.98 and its 200-day moving average price is $46.48.
Bristol-Myers Squibb Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.39%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.
Analysts Set New Price Targets
Read Our Latest Report on Bristol-Myers Squibb
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Bristol-Myers Squibb
- What is the Dogs of the Dow Strategy? Overview and Examples
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What Makes a Stock a Good Dividend Stock?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- Buy P&G Now, Before It Sets A New All-Time High
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.